Advertisement

Hyperreflective foci in Stargardt disease: 1-year follow-up

  • Maurizio Battaglia Parodi
  • Riccardo Sacconi
  • Francesco Romano
  • Francesco Bandello
Retinal Disorders
  • 50 Downloads

Abstract

Purpose

To describe the hyperreflective foci (HF) characteristics in eyes affected by Stargardt disease (STGD), correlating HF with the atrophy progression at 1-year follow-up.

Methods

Prospective observational case series with 1-year follow-up. Twenty-eight eyes (14 patients) affected by STGD and 28 eyes (14 age- and sex-matched healthy patients) used as control group were recruited. All patients underwent a complete ophthalmologic examination including fundus autofluorescence and spectral-domain optical coherence tomography. The primary outcome was the identification of HF specific location in STGD and their modification over a 1-year follow-up. Secondary outcome included the correlation between the number and the location of HF and atrophic changes.

Results

HF turned out to be more frequent in STGD patients compared with healthy controls (p < 0.001). In particular, mean number of HF in the pathological edge was significantly higher than in the healthy edge of the atrophy (p < 0.001) and in the foveal area (p < 0.001). A negative correlation was found between the total HF number in the pathological edge and the atrophic area at baseline. HF number in the outer retina of the pathological edge significantly decreased between the baseline and the final follow-up examination (p = 0.011). The enlargement of the atrophic area in eyes with more than five outer retinal HF in the pathological edge at baseline was significantly less than that found in the eyes with fewer than five HF (p = 0.010).

Conclusions

HF are most common at the pathological margin of the central atrophy, with outer retina foci being more frequently found in smaller atrophic lesions.

Keywords

Hyperreflective foci Optical coherence tomography Stargardt disease 

Notes

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

All authors have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.

Maurizio Battaglia Parodi, Riccardo Sacconi and Francesco Romano: none.

Francesco Bandello is a consultant for Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc. (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), and Zeiss (Dublin, USA).

The authors have no proprietary interest in the materials used in this study.

References

  1. 1.
    Bolz M, Schmidt-Erfurth U, Deak G, Diabetic Retinopathy Research Group Vienna et al (2009) Optical coherence tomographic hyper-reflective foci: a morphological sign of lipid extravasation in diabetic macular edema. Ophthalmology 116:914–920CrossRefGoogle Scholar
  2. 2.
    Ogino K, Murakami T, Tsujikawa A et al (2012) Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina 32:77–85CrossRefGoogle Scholar
  3. 3.
    Christenbury JG, Folgar FF, O’Connell R et al (2013) Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 120:1038–1045CrossRefGoogle Scholar
  4. 4.
    Coscas G, De Benedetto U, Coscas F et al (2013) Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 229:32–37CrossRefGoogle Scholar
  5. 5.
    De Benedetto U, Sacconi R, Pierro L, Lattanzio R, Bandello F (2015) Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina 35:449–453CrossRefGoogle Scholar
  6. 6.
    Kuroda M, Hirami Y, Hata M, Mandai M, Takahashi M, Kurimoto Y (2014) Intraretinal hyperreflective foci on spectral-domain optical coherence tomography images of patients with retinitis pigmentosa. Clin Ophthalmol 8:435–440CrossRefGoogle Scholar
  7. 7.
    Piri N, Nesmith BLW, Schaal S (2015) Choroidal hyperreflective foci in Stargardt disease shown by spectral-domain optical coherence tomography imaging. Correlation with disease severity. JAMA Ophthalmol 133:398–405CrossRefGoogle Scholar
  8. 8.
    Chen KC, Jung JJ, Curcio CA et al (2016) Intraretinal hyperreflective foci in acquired vitelliform lesions of the macula: clinical and histologic study. Am J Ophthalmol 164:89–98CrossRefGoogle Scholar
  9. 9.
    Battaglia Parodi M, Iacono P, Romano F, Bolognesi G, Fasce F, Bandello F (2017) Optical coherence tomography in Best vitelliform macular dystrophy. Eur J Ophthalmol 27:201–204CrossRefGoogle Scholar
  10. 10.
    Battaglia Parodi M, Iacono P, Romano F, Bandello F (2017) Spectral domain optical coherence tomography features in different stages of best vitelliform macular dystrophy. Retina.  https://doi.org/10.1097/IAE.0000000000001634
  11. 11.
    Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL, Hockey RR (1999) Variation of clinical expression in patients with Stargardt dystrophy and sequence variations in the ABCR gene. Arch Ophthalmol 117:504–510CrossRefGoogle Scholar
  12. 12.
    Grisanti S, Guidry C (1995) Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci 36:391–405Google Scholar
  13. 13.
    Kim JW, Kang KH, Burrola P, Mak TW, Lemke G (2008) Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev 22:3147–3157CrossRefGoogle Scholar
  14. 14.
    Sennlaub F, Auvynet C, Calippe B et al (2013) CCR2(+) monocytes infiltrate atrophic lesions in age-related macular disease and mediate photoreceptor degeneration in experimental subretinal inflammation in Cx3cr1 deficient mice. EMBO Mol Med 5:1775–1793CrossRefGoogle Scholar
  15. 15.
    Lad EM, Cousins SW, Van Arnam JS, Proia AD (2015) Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253:1941–1945CrossRefGoogle Scholar
  16. 16.
    Harada T, Harada C, Kohsaka S et al (2002) Microglia-Muller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci 22:9228–9236CrossRefGoogle Scholar
  17. 17.
    Arroba AI, Alvarez-Lindo N, van Rooijen N, de la Rosa EJ (2014) Microglia-Müller glia crosstalk in the rd10 mouse model of retinitis pigmentosa. Adv Exp Med Biol 801:373–379CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Ophthalmology, IRCCS Ospedale San RaffaeleUniversity Vita-SaluteMilanItaly
  2. 2.Eye Clinic, Department of Neurological, Biomedical and Movement SciencesUniversity of VeronaVeronaItaly

Personalised recommendations